These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33815827)

  • 1. Idarucizumab (Praxbind
    Kalmanovich E; Battistella P; Rouviere P; Albat B; Frapier JM; Demaria R; Huet F; Agullo A; Mourad M; Colson P; Leclercq F; Gaudard P; Roubille F
    Future Sci OA; 2021 Feb; 7(4):FSO689. PubMed ID: 33815827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study.
    Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Kimoto T; Nakayama D
    Cardiol Ther; 2023 Dec; 12(4):723-740. PubMed ID: 37845427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience with idarucizumab as a reverse agent of dabigatran].
    Bottaro FJ; Margan MM; Duboscq C; Ceresetto JM
    Medicina (B Aires); 2020; 80(4):405-410. PubMed ID: 32841148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.
    Izaguirre Ávila R; Bahena López JE; Cortina de la Rosa E; Hernández Márquez MÁ
    Eur Heart J Case Rep; 2019 Jun; 3(2):. PubMed ID: 31449648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
    Fagundes V; Mesquita M
    Eur J Case Rep Intern Med; 2019; 6(12):001311. PubMed ID: 31893202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dabigatran Reversal: A Practical Approach].
    Ricca Gonçalves L; Robalo Nunes A
    Acta Med Port; 2022 May; 35(5):394-398. PubMed ID: 36279894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran reversal with idarucizumab prior to lung transplantation.
    Harano T; Rivosecchi RM; Morrell MR; Sanchez PG
    Clin Transplant; 2021 Jan; 35(1):e14142. PubMed ID: 33150658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
    Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
    J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M
    Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.